公开发行的可转换公司债券（以下简称"润达转债"或"本期债券"）将于 2025 年 6 月 17 日开始支付自 2024 年 6 月 17 日至 2025 年 6 月 16 日期间的利息。根 据《上海润达医疗科技股份有限公司公开发行可转换公司债券募集说明书》（以 下简称"《募集说明书》"）相关条款的规定，现将相关事项公告如下： 一、可转债发行上市概况 （一）债券名称：上海润达医疗科技股份有限公司可转换公司债券 （七）票面金额和发行价格：每张面值为人民币 100 元，按面值发行。 证券代码：603108 证券简称：润达医疗 公告编号：临 2025-027 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 关于"润达转债"2025 年付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 可转债付息债权登记日：2025 年 6 月 16 日 ● 可转债除息日：2025 年 6 月 17 日 ● 可转债兑息日：2025 年 6 月 17 日 上海润达医疗科技股份有限公司（以下简称"公司"） ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-027 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于"润达转债"2025 年付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ● 可转债付息债权登记日：2025 年 6 月 16 日 ● 可转债除息日：2025 年 6 月 17 日 ● 可转债兑息日：2025 年 6 月 17 日 （一）债券名称：上海润达医疗科技股份有限公司可转换公司债券 （二）债券简称：润达转债 （三）债券代码：113588 （四）债券类型：可转换为公司 A 股股票的可转换公司债券 （五）发行规模：人民币 55,000 万元 （六）发行数量：5,500,000 手（550,000 张） （七）票面金额和发行价格：每张面值为人民币 100 元，按面值发行。 （八）债券期限：本次发行的可转换公司债券的期限为自发行之日起 6 年， 即 2020 年 6 月 17 日至 2026 年 ...

Core Viewpoint - Jinan Runda Biotechnology Co., Ltd. was fined 600,000 yuan for commercial bribery related to the sale of automatic coagulation analyzers and associated consumables [1][4]. Company Summary - Jinan Runda was found to have engaged in commercial bribery by selling automatic coagulation analyzers and related consumables at low prices to hospitals, thereby gaining more trading opportunities [1][3]. - The company was established in 2014, with a registered capital of 50.5 million yuan, and is primarily owned by Shanghai Runda Medical Technology Co., Ltd., which holds a 70% stake [5]. - The legal representative of Jinan Runda is Li Jie [5]. Parent Company Summary - Shanghai Runda Medical Technology Co., Ltd. was founded in 1999 and went public in 2015. As of March 10, 2025, the largest shareholder is Hangzhou Gongshu District State-owned Investment Group Co., Ltd., holding 19.22% [6]. - Runda Medical acknowledged the commercial bribery incident and stated that it is cooperating with regulatory authorities for investigation and corrective actions [6]. - The company is involved in the IVD (in vitro diagnostics) distribution and service industry, providing diagnostic products and technical support to medical laboratories [6]. Financial Performance - Runda Medical's performance has declined significantly in recent years. In 2024, the company reported revenue of 8.312 billion yuan, a decrease of 9.13% year-on-year, and net profit dropped from 273 million yuan to 55 million yuan, a decline of 79.77% [6][8]. - In the first quarter of 2025, the company reported revenue of 1.662 billion yuan, down 19.81% year-on-year, and a net loss of 69 million yuan, marking a 406.40% decline [8][9]. - The company's total expenses (sales, management, and financial) reached 1.634 billion yuan in 2024, accounting for 19.66% of revenue, an increase of 0.62 percentage points year-on-year [8].

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-025 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2024 年度股东大会审议通过：自 2025 年 5 月 27 日至 2025 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 422,100 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：六家全资子公司：杭州润达、惠中医疗、润达供应链杭 州、中鼎达科、青岛益信、惠中诊断；七家控股子公司：合肥润达、云 南康泰、合肥三立、润达榕嘉、杭州 ...

上海泽昌律师事务所 关于上海润达医疗科技股份有限公司 2024年年度股东大会的 法律意见书 上海市浦东新区世纪大道 1589 号长泰国际金融大厦 11 层 电话：021-61913137 传真：021-61913139 邮编：200122 二〇二五年五月 上海泽昌律师事务所 法律意见书 上海泽昌律师事务所 关于上海润达医疗科技股份有限公司 2024 年年度股东大会的 法律意见书 泽昌证字 2025-01-12-01 致：上海润达医疗科技股份有限公司 另，鉴于新《公司法》已于 2024 年 7 月 1 日生效、《上市公司股东会规则》 （证监会公告〔2025〕7 号）已于 2025 年 3 月 28 日生效，"股东大会"已改称 "股东会"，但为与公司发布的公告保持一致，本次仍称"股东大会"。 1 上海泽昌律师事务所 法律意见书 一、本次股东大会召集人资格及召集、召开的程序 （一）本次会议的召集 经核查，公司本次股东大会是由 2025 年 4 月 24 日召开的公司第五届董事会 第二十次会议决定召集的。公司已于 2025 年 4 月 26 日在《中国证券报》《上海 证券报》《证券日报》《证券时报》和上海证券交易所网 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-024 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 27 日 (二)股东大会召开的地点：上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 757 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 204,286,831 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 33.8413 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 表决情况： ...

Core Viewpoint - The China Securities Index for Food and Major Consumer Goods Retail has shown a decline in performance over various time frames, indicating potential challenges in the sector [1][2]. Group 1: Index Performance - The China Securities Index for Food and Major Consumer Goods Retail is currently at 9719.75 points, having decreased by 0.13% over the past month, 2.88% over the past three months, and 4.47% year-to-date [1]. - The index is based on a sample of listed companies in the food and drug retail sector, reflecting the overall performance of these securities [1]. Group 2: Index Composition - The top ten weighted companies in the index include Yonghui Supermarket (6.96%), Digital China (6.48%), Shanghai Pharmaceuticals (6.14%), Yifeng Pharmacy (4.97%), and others, indicating a concentration in a few key players [1]. - The index is primarily composed of companies listed on the Shanghai Stock Exchange (55.91%) and Shenzhen Stock Exchange (44.09%) [1]. Group 3: Industry Breakdown - The industry composition of the index shows that pharmaceutical commerce accounts for 48.65%, specialized retail for 19.84%, department stores for 16.99%, and supermarkets and convenience stores for 14.52% [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2].

Core Viewpoint - The company has decided not to exercise the early redemption rights for its convertible bonds, despite meeting the conditions for redemption, to protect investor interests and due to existing financial commitments [2][6]. Group 1: Convertible Bond Redemption - The company's stock has met the condition of having at least 15 trading days with closing prices not lower than 130% of the current conversion price over a 30-day period from April 29, 2025, to May 22, 2025, triggering the redemption clause for the "Run Da Convertible Bonds" [2][5]. - The board of directors unanimously agreed not to redeem the "Run Da Convertible Bonds" early during a meeting held on May 22, 2025, considering current market conditions and financial arrangements [6][7]. - The company will not exercise the early redemption rights for the next three months, from May 23, 2025, to August 22, 2025, even if the redemption conditions are met again [2][6]. Group 2: Convertible Bond Issuance Overview - The company issued 5,500,000 convertible bonds on June 17, 2020, with a total amount of 55 million yuan and a maturity of six years, with varying interest rates from 0.3% to 2.0% over the term [3][4]. - The initial conversion price was set at 13.36 yuan per share, which has been adjusted multiple times due to profit distributions, currently standing at 13.10 yuan per share as of July 18, 2023 [3][4]. Group 3: Related Party Transactions - The company's actual controllers, major shareholders, and senior management have not held "Run Da Convertible Bonds" in the six months prior to the redemption conditions being met and have no plans to reduce their holdings in the next six months [7].

Industry Overview and Core Value - AI in healthcare utilizes machine learning and computer vision to analyze medical data, aiming to enhance efficiency, reduce costs, and optimize patient experience [1][14] - The Chinese government has introduced policies to promote AI integration in healthcare, identifying 84 application scenarios [1][22] Development History and Market Size - The development of AI in healthcare in China can be divided into three phases: the nascent phase (1978-2015), the starting phase (2015-2021), and the exploratory phase (2021-present) [2][25] - The market size for AI healthcare in China is projected to reach 115.7 billion yuan by 2025 and 159.8 billion yuan by 2028, with a CAGR of 10.5% [2][39] Industry Chain and Segmentation - The AI healthcare industry chain includes upstream (data, algorithms, computing power), midstream (computer vision, NLP), and downstream (imaging, pharmaceuticals, health management) [3][43] - Key segments include: - AI Medical Imaging: Expected market size of approximately 7.45 billion yuan in 2024, growing to 23.57 billion yuan by 2026 [3] - AI Pharmaceuticals: Global market size projected at 2.994 billion USD in 2024 [3] - AI Health Management: Market size nearing 1.4 trillion yuan in 2024 [3] Challenges and Future Trends - Current challenges include insufficient data standardization, privacy protection, and high implementation costs [4] - Future trends involve: - Deepening technology integration, such as combining large models with multimodal technologies [4] - Promoting domestic production and self-control in hardware and algorithms [4] - Expanding application scenarios from hospitals to grassroots healthcare [4] - Policy-driven commercialization in areas like telemedicine and imaging recognition [4] Representative Company Layout - Key companies in the AI healthcare sector include: - Xiangsheng Medical: Portable ultrasound devices recognized internationally [5] - RunDa Medical: Integration of in vitro diagnostics with AI [5] - United Imaging: High-end imaging equipment with over 20% market share [5] - iFlytek Medical: Comprehensive coverage of the medical process with its large model [5]

公司股票自 2025 年 4 月 29 日至 2025 年 5 月 22 日期间，已满足连 续三十个交易日中至少有十五个交易日的收盘价不低于当期转股价格的 130%（含 130%），已触发"润达转债"的赎回条款。公司董事会决定本次 不行使"润达转债"的提前赎回权利，不提前赎回"润达转债"。 未来三个月内（即 2025 年 5 月 23 日至 2025 年 8 月 22 日），如公司 触发"润达转债"的赎回条款均不行使"润达转债"的提前赎回权利。以 2025 年 8 月 22 日之后的首个交易日重新起算，若"润达转债"再次触发赎回条 款，届时公司董事会将再次召开会议决定是否行使"润达转债"的提前赎回 权利。 一、可转债发行上市概况 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-023 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于不提前赎回"润达转债"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和 ...